JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers
Xuxiu Lu, Rilei Yu, Zhen Li, Mengke Yang, Jiajia Dai, Ming Liu
Topics & Concepts
Cancer researchGefitinibT790MReceptor tyrosine kinaseOsimertinibCancer cellMAPK/ERK pathwayVemurafenibProto-oncogene tyrosine-protein kinase SrcBiologyTyrosine kinaseAllosteric regulationCancerKinaseSignal transductionEpidermal growth factor receptorCell biologyReceptorErlotinibBiochemistryGeneticsMetastatic melanomaMelanomaProtein Tyrosine PhosphatasesPI3K/AKT/mTOR signaling in cancerGalectins and Cancer Biology